SunTrust Robinson Humphrey Downgrades Global Blood Therapeutics to Hold

SunTrust Robinson Humphrey analyst John Lee downgrades Global Blood Therapeutics (NASDAQ:GBT) from Buy to Hold.

Benzinga · 01/31/2020 12:33

SunTrust Robinson Humphrey analyst John Lee downgrades Global Blood Therapeutics (NASDAQ:GBT) from Buy to Hold.